Fluor to Manage Construction of Large-Scale Biologics Manufacturing Facility

Trending News 🌥️

Fluor Corporation ($NYSE:FLR) has been selected to lead procurement and construction management for a large-scale biologics drug substance manufacturing facility located in Scandinavia. Construction is already underway. The facility, which is being built by an international consortium, will be one of the largest of its kind in the world and will use cutting-edge technology to produce biologic drugs. Fluor has a long history of successful construction projects in the life sciences sector, and we are confident that we will deliver this project on time and on budget.

Stock Price

The facility will be located in the United States and is expected to be operational by 2022. The announcement caused Fluor’s stock to open at $24.7 and close at $24.4, down by 1.5% from its previous closing price of $24.8. Fluor is a global engineering, procurement, construction, and maintenance company that has worked on some of the world’s largest and most complex projects. The company has a long history of successfully delivering projects in the life sciences sector, and this experience was a key factor in its selection for this project. The new facility will be used to manufacture biologic medicines, which are made from living cells.

These medicines are used to treat a wide range of conditions, including cancer, autoimmune diseases, and genetic disorders. The announcement of Fluor’s involvement in this project comes as the global biologics market is expected to grow rapidly in the coming years. This project is another example of Fluor’s commitment to helping its clients meet the challenges of the rapidly changing healthcare landscape.

VI Analysis

Company’s fundamentals reflect its long term potential.

However, there are some risks associated with investing in FLUOR CORPORATION that investors should be aware of. According to VI’s Risk Rating, FLUOR CORPORATION is a medium risk investment in terms of financial and business aspects. This means that there are some potential risks associated with the company’s financial stability and business operations that investors should be aware of. Some of the risks associated with FLUOR CORPORATION include its high debt levels, which could put pressure on the company’s cash flow and earnings.

Additionally, the company’s business is dependent on the oil and gas industry, which has been volatile in recent years.

Summary

Fluor Corporation announced today that it was awarded a contract by Biogen to provide program management services for the construction of a large-scale biologics manufacturing facility in Solothurn, Switzerland. Fluor has a long history of delivering complex projects in the life sciences sector, including biopharmaceutical and vaccine manufacturing facilities. This experience, along with our program management expertise, will be leveraged on this project to ensure a successful outcome for our client. The new facility will be used to manufacture Biogen’s next-generation therapies.

It will be one of the largest and most advanced biologics manufacturing facilities in the world. Fluor is committed to helping Biogen bring these life-changing therapies to patients around the globe. We are honored to be part of this important project.